CCL

Összesen 8 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM080579
035-os BibID:(WoS)000476957100010 (Scopus)85068205459 (PMID)31243960
Első szerző:Barr, Daniel
Cím:Identification of C-[béta]-d-Glucopyranosyl Azole-Type Inhibitors of Glycogen Phosphorylase That Reduce Glycogenolysis in Hepatocytes : in Silico Design, Synthesis, in Vitro Kinetics, and ex Vivo Studies / Daniel Barr, Eszter Szennyes, Éva Bokor, Ziad H. Al-Oanzi, Colin Moffatt, Sándor Kun, Tibor Docsa, Ádám Sipos, Matthew P. Davies, Rachel T. Mathomes, Timothy J. Snape, Loranne Agius, László Somsák, Joseph M. Hayes
Dátum:2019
ISSN:1554-8929
Megjegyzések:Several C-β-d-glucopyranosyl azoles have recently been uncovered as among the most potent glycogen phosphorylase (GP) catalytic site inhibitors discovered to date. Toward further exploring their translational potential, ex vivo experiments have been performed for their effectiveness in reduction of glycogenolysis in hepatocytes. New compounds for these experiments were predicted in silico where, for the first time, effective ranking of GP catalytic site inhibitor potencies using the molecular mechanics-generalized Born surface area (MM-GBSA) method has been demonstrated. For a congeneric training set of 27 ligands, excellent statistics in terms of Pearson (RP) and Spearman (RS) correlations (both 0.98), predictive index (PI = 0.99), and area under the receiver operating characteristic curve (AU-ROC = 0.99) for predicted versus experimental binding affinities were obtained, with ligand tautomeric/ionization states additionally considered using density functional theory (DFT). Seven 2-aryl-4(5)-(β-d-glucopyranosyl)-imidazoles and 2-aryl-4-(β-d-glucopyranosyl)-thiazoles were subsequently synthesized, and kinetics experiments against rabbit muscle GPb revealed new potent inhibitors with best Ki values in the low micromolar range (5c = 1.97 ?M; 13b = 4.58 ?M). Ten C-β-d-glucopyranosyl azoles were then tested ex vivo in mouse primary hepatocytes. Four of these (5a-c and 9d) demonstrated significant reduction of glucagon stimulated glycogenolysis (IC50 = 30-60 ?M). Structural and predicted physicochemical properties associated with their effectiveness were analyzed with permeability related parameters identified as crucial factors. The most effective ligand series 5 contained an imidazole ring, and the calculated pKa (Epik: 6.2; Jaguar 5.5) for protonated imidazole suggests that cellular permeation through the neutral state is favored, while within the cell, there is predicted more favorable binding to GP in the protonated form.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Acs Chemical Biology. - 14 : 7 (2019), p. 1460-1470. -
További szerzők:Szennyes Eszter (1989-) (vegyész) Bokor Éva (1982-) (vegyész) Al-Oanzi, Ziad H. Moffatt, Colin Kun Sándor (1984-) (vegyész) Docsa Tibor (1975-) (vegyész, biokémikus) Sipos Ádám (1992-) (gyógyszerész) Davies, Matthew P. Mathomes, Rachel T. Snape, Timothy J. Agius, Loranne Somsák László (1954-) (vegyész) Hayes, Joseph M.
Pályázati támogatás:GINOP-2.3.2-15-2016-00008
GINOP
GINOP-2.3.3-15-2016-00004
GINOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM056763
Első szerző:Begum, Jaida
Cím:Computationally motivated synthesis and enzyme kinetic evaluation of N-([beta]-D-glucopyranosyl)-1,2,4-triazolecarboxamides as glycogen phosphorylase inhibitors / Jaida Begum, Gergely Varga, Tibor Docsa, Pal Gergely, Joseph M. Hayes, Laszló Juhász, Laszló Somsák
Dátum:2015
ISSN:2040-2503 2040-2511
Megjegyzések:Following our recent study of N-(b-D-glucopyranosyl)oxadiazolecarboxamides (Polyák et al., Biorg. Med. Chem. 2013, 21, 5738) revealed as moderate inhibitors of glycogen phosphorylase (GP), in silico docking calculations using Glide have been performed on N-(?-D-glucopyranosyl)-1,2,4-triazolecarboxamides with different aryl substituents predicting more favorable binding at GP. The ligands were subsequently synthesized in moderate yields using N-(2,3,4,6-tetra-O-acetyl-?-D-glucopyranosyl)-tetrazole-5-carboxamide as starting material. Kinetics experiments against rabbit muscle glycogen phosphorylase b (RMGPb) revealed the ligands to be low mM GP inhibitors; the phenyl analogue (Ki =1 mM) is one of the most potent N-(?-D-glucopyranosyl)-heteroaryl-carboxamide-type inhibitors of the GP catalytic site discovered to date. Based on QM and QM/MM calculations, the potency of the ligands is predicted to arise from favorable intra- and intermolecular hydrogen bonds formed by the most stable solution phase tautomeric (t2) state of the 1,2,4-triazole in a conformationally dynamic system. ADMET property predictions revealed the compounds to have promising pharmacokinetic properties without any toxicity. This study highlights the benefits of a computationally led approach to GP inhibitor design.
Tárgyszavak:Természettudományok Kémiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban
Doktori iskola
Megjelenés:MedChemComm. - 6 : 1 (2015), p. 80-89. -
További szerzők:Varga Gergely (1982-) (vegyész) Docsa Tibor (1975-) (vegyész, biokémikus) Gergely Pál (1947-) (biokémikus) Hayes, Joseph M. Juhász László (1973-) (vegyész) Somsák László (1954-) (vegyész)
Pályázati támogatás:77712
OTKA
109450
OTKA
TÁMOP-4.2.2-08/1-2008-0014
TÁMOP
TÁMOP-4.2.2/B-10/1-2010-0024
TÁMOP
Kémiai Tudományok Doktori Iskola
BAROSS REG_EA_09-1-2009-0028-LCMS_TAN
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM099884
035-os BibID:(cikkazonosító)1037 (scopus)85122862338 (wos)000754896600001
Első szerző:Kiss Mariann (vegyész)
Cím:2-Acetamido-2-deoxy-d-glucono-1,5-lactone Sulfonylhydrazones: Synthesis and Evaluation as Inhibitors of Human OGA and HexB Enzymes / Mariann Kiss, István Timári, Teréz Barna, Zuzana Mészáros, Kristýna Slámová, Pavla Bojarová, Vladimír Křen, Joseph M. Hayes, László Somsák
Dátum:2022
ISSN:1661-6596 1422-0067
Megjegyzések:Inhibition of the human O-linked ?-N-acetylglucosaminidase (hOGA, GH84) enzyme is pharmacologically relevant in several diseases such as neurodegenerative and cardiovascular disorders, type 2 diabetes, and cancer. Human lysosomal hexosaminidases (hHexA and hHexB, GH20) are mechanistically related enzymes; therefore, selective inhibition of these enzymes is crucial in terms of potential applications. In order to extend the structure?activity relationships of OGA inhibitors, a series of 2-acetamido-2-deoxy-D-glucono-1,5-lactone sulfonylhydrazones was prepared from D-glucosamine. The synthetic sequence involved condensation of N-acetyl-3,4,6-tri-O-acetylD-glucosamine with arenesulfonylhydrazines, followed by MnO2 oxidation to the corresponding glucono-1,5-lactone sulfonylhydrazones. Removal of the O-acetyl protecting groups by NH3/MeOH furnished the test compounds. Evaluation of these compounds by enzyme kinetic methods against hOGA and hHexB revealed potent nanomolar competitive inhibition of both enzymes, with no significant selectivity towards either. The most efficient inhibitor of hOGA was 2-acetamido-2-deoxyD-glucono-1,5-lactone 1-naphthalenesulfonylhydrazone (5f, Ki = 27 nM). This compound had a Ki of 6.8 nM towards hHexB. To assess the binding mode of these inhibitors to hOGA, computational studies (Prime protein?ligand refinement and QM/MM optimizations) were performed, which suggested the binding preference of the glucono-1,5-lactone sulfonylhydrazones in an s-cis conformation for all test compounds.
Tárgyszavak:Természettudományok Kémiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
hOGA
hHexB
inhibitor
glyconolactone sulfonylhydrazone
Prime refinement
QM/MM optimization
Megjelenés:International Journal of Molecular Sciences. - 23 : 3 (2022), p. 1-18. --
További szerzők:Timári István (1989-) (vegyész) Barna Teréz (1963-) (vegyész) Mészáros, Zuzana Slámová, Kristýna Bojarová, Pavla Křen, Vladimír Hayes, Joseph M. Somsák László (1954-) (vegyész)
Pályázati támogatás:K109450
OTKA
FK-125067
OTKA
PD 135034
OTKA
GINOP-2.3.2-15-2016-00008
GINOP
GINOP-2.3.3-15-2016-00004
GINOP
ÚNKP-21-5-DE-471
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM096569
035-os BibID:(cikkazonosító)113649 (WoS)000695696100030 (Scopus)85109505021
Első szerző:Kiss Mariann (vegyész)
Cím:Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives / Mariann Kiss, Erna Szabó, Boglárka Bocska, Luu Thanh Sinh, Conceicao Piedade Fernandes, István Timári, Joseph M. Hayes, László Somsák, Teréz Barna
Dátum:2021
ISSN:0223-5234
Megjegyzések:O-GlcNAcylation is a dynamic post-translational modification mediated by O-linked beta-N-acetylglucosamine transferase (OGT) and O-GlcNAc hydrolase (OGA), that adds or removes a single beta-N-acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively. The perturbed homeostasis of O-GlcNAc cycling results in several pathological conditions. Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O-GlcNAc are experienced, such as tauopathy in Alzheimer's disease. A new class of potent OGA inhibitors, 2-acetamido-2-deoxy-D-glucono-1,5-lactone (thio)semicarbazones, have been identified. Eight inhibitors were designed and synthesized in five steps starting from d-glucosamine and with 15-55% overall yields. A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph. Thermal denaturation kinetics of hOGA revealed environmental factors affecting hOGA stability. From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with K-i-s in the range of similar to 30-250 nM and moderate selectivity with respect to lysosomal beta-hexosaminidases. In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy-D-glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (K-i = 36 nM). The protocol employed has applications in future structure based inhibitor design targeting OGA. (C) 2021 The Authors. Published by Elsevier Masson SAS.
Tárgyszavak:Természettudományok Kémiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
hOGA
Expression
Inhibitor
Glyconolactone semicarbazone
QM/MM-PBSA
Halogen
HalogenHydrogen bond donor
Megjelenés:European Journal of Medicinal Chemistry. - 223 (2021), p. 1-14. -
További szerzők:Szabó Erna (1990-) (Biológus) Bocska Boglárka Sinh, Luu Thanh Fernandes, Conceicao Piedade Timári István (1989-) (vegyész) Hayes, Joseph M. Somsák László (1954-) (vegyész) Barna Teréz (1963-) (vegyész)
Pályázati támogatás:K 109450
OTKA
NKFIH FK125067
Egyéb
NKFIH PD 135034
Egyéb
GINOP-2.3.2-15-2016-00008
GINOP
GINOP-2.3.3-15-2016-00004
GINOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM110220
035-os BibID:(cikkazonosító)3005 (Scopus)85152313558 (WoS)000968814700001
Első szerző:Kun Sándor (vegyész)
Cím:Design and Synthesis of 3-(β-D-Glucopyranosyl)-4-amino/4-guanidino Pyrazole Derivatives and Analysis of Their Glycogen Phosphorylase Inhibitory Potential / Kun Sándor, Mathomes Rachel T., Docsa Tibor, Somsák László, Hayes Joseph M.
Dátum:2023
ISSN:1420-3049
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Molecules. - 28 : 7 (2023), p. 1-19. -
További szerzők:Mathomes, Rachel T. Docsa Tibor (1975-) (vegyész, biokémikus) Somsák László (1954-) (vegyész) Hayes, Joseph M.
Pályázati támogatás:FK132222
NKFIH
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM072396
Első szerző:Kun Sándor (vegyész)
Cím:A multidisciplinary study of 3-(β-D-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors : computation, synthesis, crystallography and kinetics reveal new potent inhibitors / Sandor Kun, Jaida Begum, Efthimios Kyriakis, Evgenia C. V. Stamati, Thomas A. Barkas, Eszter Szennyes, Eva Bokor, Katalin E. Szabo, George A. Stravodimos, Adam Sipos, Tibor Docsa, Pal Gergely, Colin Moffatt, Myrto S. Patraskaki, Maria C. Kokolaki, Alkistis Gkerdi, Vassiliki T. Skamnaki, Demetres D. Leonidas, Laszló Somsák, Joseph M. Hayes
Dátum:2018
ISSN:0223-5234
Megjegyzések:3-(β-D-Glucopyranosyl)-5-substituted-1,2,4-triazoles have been revealed as an effective scaffold for the development of potent glycogen phosphorylase (GP) inhibitors but with the potency very sensitive to the nature of the alkyl/aryl 5-substituent (Kun et al., Eur. J. Med. Chem. 2014, 76, 567). For a training set of these ligands, quantum mechanics-polarized ligand docking (QM-PLD) demonstrated good potential to identify larger differences in potencies (predictive index PI = 0.82) and potent inhibitors with Ki's < 10 ?M (AU-ROC = 0.86). Accordingly, in silico screening of 2335 new analogues exploiting the ZINC docking database was performed and nine predicted candidates selected for synthesis. The compounds were prepared in O-perbenzoylated forms by either ring transformation of 5-?-D-glucopyranosyl tetrazole by N-benzyl-arenecarboximidoyl chlorides, ring closure of C-(?-D-glucopyranosyl)formamidrazone with aroyl chlorides, or that of N-(?-D-glucopyranosylcarbonyl)arenethiocarboxamides by hydrazine, followed by deprotections. Kinetics experiments against rabbit muscle GPb (rmGPb) and human liver GPa (hlGPa) revealed five compounds as potent low ?M inhibitors with three of these on the submicromolar range for rmGPa. X-ray crystallographic analysis sourced the potency to a combination of favorable interactions from the 1,2,4-triazole and suitable aryl substituents in the GP catalytic site. The compounds also revealed promising calculated pharmacokinetic profiles.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
1,2,4-Triazole
C-[beta]-D-glucopyranosyl derivatives
Glycogen phosphorylase inhibitors
QM/MM docking
Kinetics
X-ray crystallography
Megjelenés:European Journal of Medicinal Chemistry 147 (2018), p. 266-278. -
További szerzők:Begum, Jaida Kyriakis, Efthimios Stamati, Evgenia C. V. Barkas, Thomas A. Szennyes Eszter (1989-) (vegyész) Bokor Éva (1982-) (vegyész) Szabó Erzsébet Katalin (1989-) (vegyész) Stravodimos, George A. Sipos Ádám (1992-) (gyógyszerész) Docsa Tibor (1975-) (vegyész, biokémikus) Gergely Pál (1947-) (biokémikus) Moffatt, Colin Patraskaki, Myrto S. Kokolaki, Maria C. Gkerdi, Alkistis Skamnaki, Vassiliki T. Leonidas, Demetres D. Somsák László (1954-) (vegyész) Hayes, Joseph M.
Pályázati támogatás:PD 105808
OTKA
PD 121406
OTKA
GINOP-2.3.2-15-2016-00008
GINOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM047544
035-os BibID:PMID:23938052
Első szerző:Polyák Mária
Cím:Synthesis, enzyme kinetics and computational evaluation of N-(β-d-glucopyranosyl) oxadiazolecarboxamides as glycogen phosphorylase inhibitors / Mária Polyák, Gergely Varga, Bence Szilágyi, László Juhász, Tibor Docsa, Pál Gergely, Jaida Begum, Joseph M. Hayes, László Somsák
Dátum:2013
ISSN:0968-0896
Megjegyzések:All possible isomers of N-β-d-glucopyranosyl aryl-substituted oxadiazolecarboxamides were synthesised. O-Peracetylated N-cyanocarbonyl-β-d-glucopyranosylamine was transformed into the corresponding N-glucosyl tetrazole-5-carboxamide, which upon acylation gave N-glucosyl 5-aryl-1,3,4-oxadiazole-2-carboxamides. The nitrile group of the N-cyanocarbonyl derivative was converted to amidoxime which was ring closed by acylation to N-glucosyl 5-aryl-1,2,4-oxadiazole-3-carboxamides. A one-pot reaction of protected β-d-glucopyranosylamine with oxalyl chloride and then with arenecarboxamidoximes furnished N-glucosyl 3-aryl-1,2,4-oxadiazole-5-carboxamides. Removal of the O-acetyl protecting groups by the Zemplén method produced test compounds which were evaluated as inhibitors of glycogen phosphorylase. Best inhibitors of these series were N-(β-d-glucopyranosyl) 5-(naphth-1-yl)-1,2,4-oxadiazol-3-carboxamide (Ki=30M), N-(β-d-glucopyranosyl) 5-(naphth-2-yl)-1,3,4-oxadiazol-2-carboxamide (Ki=33M), and N-(β-d-glucopyranosyl) 3-phenyl-1,2,4-oxadiazol-5-carboxamide (Ki=104M). ADMET property predictions revealed these compounds to have promising oral drug-like properties without any toxicity. Copyright © 2013 Elsevier Ltd. All rights reserved.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
1,2,4-Oxadiazole
ADMET
Glycogen phosphorylas
Inhibitor
β-d-Glucopyranosyl derivatives
Molekuláris Medicina
Doktori iskola
Megjelenés:Bioorganic & Medicinal Chemistry. - 21 : 18 (2013), p. 5738-5747. -
További szerzők:Varga Gergely (1982-) (vegyész) Szilágyi Bence Juhász László (1973-) (vegyész) Docsa Tibor (1975-) (vegyész, biokémikus) Gergely Pál (1947-) (biokémikus) Begum, Jaida Hayes, Joseph M. Somsák László (1954-) (vegyész)
Pályázati támogatás:TÁMOP-4.2.2-08/1-2008-0014
TÁMOP
TÁMOP-4.2.1/B-09/1/KONV-2010-0007
TÁMOP
I. Protein foszfatázok szerepe az in vitro porcdifferenciációban és a mechano-transzdukcióban II. Hypoglykaemiás szerek tervezése a glikogén foszforilázra (foszforilációval és defoszforilációval szabályozott kulcsenzim) ható molekulákkal
TÁMOP-4.2.2/B-10/1-2010-0024
TÁMOP
Molekuláris Orvostudomány Doktori Iskola
TÁMOP-4.2.4.A/2-11-1-2012-0001
TÁMOP
CK77712
OTKA
CNK80709
OTKA
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM006384
Első szerző:Somsák László (vegyész)
Cím:New inhibitors of glycogen phosphorylase as potential antidiabetic agents / L. Somsák, K. Czifrák, M. Tóth, É. Bokor, E. D. Chrysina, K.-M. Alexacou, J. M. Hayes, C. Tiraidis, E. Lazoura, D. D. Leonidas, S. E. Zographos, N. G. Oikonomakos
Dátum:2008
ISSN:0929-8673
Megjegyzések:The protein glycogen phosphorylase has been linked to type 2 diabetes, indicating the importance of this target to human health. Hence, the search for potent and selective inhibitors of this enzyme, which may lead to antihyperglycaemic drugs, has received particular attention. Glycogen phosphorylase is a typical allosteric protein with five different ligand binding sites, thus offering multiple opportunities for modulation of enzyme activity. The present survey is focused on recent new molecules, potential inhibitors of the enzyme. The biological activity can be modified by these molecules through direct binding, allosteric effects or other structural changes. Progress in our understanding of the mechanism of action of these inhibitors has been made by the determination of high-resolution enzyme inhibitor structures (both muscle and liver). The knowledge of the three-dimensional structures of protein-ligand complexes allows analysis of how the ligands interact with the target and has the potential to facilitate structure-based drug design. In this review, the synthesis, structure determination and computational studies of the most recent inhibitors of glycogen phosphorylase at the different binding sites are presented and analyzed.
Tárgyszavak:Természettudományok Kémiai tudományok idegen nyelvű folyóiratközlemény külföldi lapban
glycogen phosphorylase
inhibitor
type 2 diabetes
structure-based drug design
antidiabetic agent
Megjelenés:Current Medicinal Chemistry. - 15 : 28 (2008), p. 2933-2983. -
További szerzők:Czifrák Katalin (1978-) (vegyész) Tóth Marietta (1974-) (vegyész) Bokor Éva (1982-) (vegyész) Chrysina, Evangelia D. Alexacou, Kyra-Melinda Hayes, Joseph M. Tiraidis, Costantinos Lazoura, E. Leonidas, Demetres D. Zographos, Spyros E. Oikonomakos, George N.
Internet cím:elektronikus változat
Borító:
Rekordok letöltése1